Medical Cannabis Market in Europe 2025 Edition Size, Share & Report | 2033

 

Market Overview 2025-2033

The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is growing due to increasing legalization, rising medical applications, and expanding research initiatives. Innovations in product development, regulatory support, and patient demand are driving expansion, making it a dynamic and evolving industry.

Key Market Highlights:

✔️ Rapid market growth driven by increasing legalization and acceptance of cannabis for medical use

✔️ Rising demand for cannabis-based treatments in pain management, neurology, and oncology

✔️ Expanding research and investment in pharmaceutical-grade cannabis production and innovation

Request for a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample

Europe Medical Cannabis Market Trends and Drivers:

The Medical Cannabis Market in Europe is growing fast, thanks to new laws and better public awareness. More countries now accept that cannabis can help treat health problems. Germany, the UK, and Portugal are leading the way by making it easier for patients to get medical cannabis while keeping product quality high. In 2024, Germany fully legalized medical cannabis for conditions like chronic pain and multiple sclerosis. This caused a 40% jump in prescriptions.

The European Medicines Agency (EMA) is also speeding up the approval of cannabis-based medicines like Epidyolex, helping to build clear rules for safety and use. But not all countries are moving at the same pace. France and Italy still require special approvals for each patient, and Sweden is still very careful about allowing use.

Because of these differences, groups like the European Cannabis Advocacy Network are calling for common rules across the EU. At the same time, quality checks are getting stronger. Growers in Spain and the Netherlands now need official ISO certifications. These changes are opening the market and attracting new investors. In 2024, investment in the industry rose by 28%.

Many patients now prefer cannabis over strong painkillers or antidepressants, especially for mental and nerve-related health issues. A 2024 survey showed that 62% of people with anxiety or PTSD felt better using CBD products. This trend is rising as Europe’s population gets older—by 2030, more than 22% will be over 65, increasing demand for cannabis-based treatments.

Germany now covers medical cannabis through health insurance for seniors with chronic pain, helping 1.2 million people in 2024. Younger patients are using it too, for issues like ADHD. Platforms like Algea Care saw a 55% rise in patients under 35. Drug companies are reacting to the demand. Jazz Pharmaceuticals launched Sativex® in Spain and Poland to help people with multiple sclerosis.

Still, supply can’t keep up. In 2024, EU cannabis growing licenses only rose by 15%, while demand jumped 34%. This has led to more imports from countries like Canada and Israel. Partnerships between European and global companies are changing the market. In 2024, UK firm Curaleaf bought Aurora Europe to grow its reach in Germany, Austria, and Switzerland. Danish company Stenocare also teamed up with Poland’s Herbionica to increase production by 2026.

Research is also growing. A 2024 study from the University of Leiden and Canadian company Tilray looked at how cannabis helps with chemotherapy-related nausea. It may help shape EU health guidelines. Online services are helping more patients, too. Sites like Cannify and Vayamed link users to doctors. In Italy and Greece, online cannabis consultations rose 73% in 2024. But prices remain a problem. In France, patients can pay up to €1,200 per month for medical cannabis, while in the Netherlands, it costs just €300. High prices push some patients to buy from unregulated sources.

The Medical Cannabis Market in Europe Size is expected to pass €4.1 billion by 2027. But inflation is making it harder for smaller growers by raising costs 18%. Green practices are becoming more important—Dutch producers like Bedrocan now use only renewable energy. Patient groups are also helping drive change. In 2024, they pushed 11 countries to offer insurance for medical cannabis. Yet, challenges like stigma in Eastern Europe and delays at borders still cause problems. Looking ahead, digital tools and AI may help create more personal cannabis treatments. After 2024, these advances could shape the future of medical cannabis across Europe.

Europe Medical Cannabis Market Segmentation: 

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Medical Cannabis Market in Europe It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.

Study Period:

Base Year: 2024

Historical Year: 2019-2024

Forecast Year: 2025-2033

Breakup by Species:

• Indica

• Sativa

• Hybrid

Breakup by Derivative:

• Cannabidiol (CBD)

• Tetrahydrocannabinol (THC)

• Others

Breakup by Application:

• Cancer

• Arthritis

• Migraine

• Epilepsy

• Others

Breakup by End Use:

• Pharmaceutical Industry

• Research and Development Centers

• Others 

Breakup by Route of Administration:

• Oral Solutions and Capsules

• Smoking

• Vaporizers

• Topicals

• Others

Breakup by Country:

• Germany

• France

• United Kingdom

• Italy

• Spain

• Others

Competitive Landscape:

The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.

Contact Us: 

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145